Purchase this article with an account.
Mario J. Saldanha, Christopher P. Blyth; A Comparison of outcomes of responders to ranibizumab at 16 weeks Vs 104 weeks - results of a 2 year follow-up. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4401.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To predict the outcomes of patient responses to ranibizumab at 2 years from their response at 16 weeks.
Prospective audit of all patients who received intravitreal Ranibizumab in Lucentis clinics from February 2008 at 2 units in South Wales, United KingdomAll patients received initial 3 loading doses of Ranibizumab and subsequent injections were based on BCVA and CRT measurements. The visual improvement and change in CRT was plotted on a scatter diagram at 16 weeks and compared with the same data at 52 and 104 weeks. 934 patients were identified and included in the study at 16 weeks. Patients were categorised into 4 groups and analysed - non-responders, partial responders, structural damage and full responders
At 1 year(52 weeks)73% of the full responders group continued to have a full response, 3 % were non-responders, 12% developed structural damage, 10% showed a partial response as compared to 16 weeks. At 2 years 63% of this group continued to be full responders, 7 % became non-responders, 17% developed structural damage and 10% showed partial response.
Based on VA and CRT changes - a good response at 16-weeks is associated with a positive outcome at 52- and 104 weeks.
This PDF is available to Subscribers Only